Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Sader, Helio S. [UNIFESP]
Rhomberg, Paul R.
Farrell, David J.
Jones, Ronald N.
Is part ofAntimicrobial Agents and Chemotherapy
MetadataShow full item record
CXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam), and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-characterized clinical strains collected worldwide, including ceftazidime-resistant members of the family Enterobacteriaceae and Klebsiella pneumoniae carbapenemase (KPC)- and extended-spectrum beta-lactamase (ESBL)-producing strains of Pseudomonas aeruginosa and Bacteroides fragilis. CXA-201 was 2- to 32-fold more active than ceftazidime and piperacillin-tazobactam against ceftazidime-resistant Enterobacteriaceae species but less active than cefepime for some species. CXA-101 and CXA-201 were very active against P. aeruginosa (MIC(50), 1 mu g/ml for both compounds), including imipenem-resistant strains.
CitationAntimicrobial Agents and Chemotherapy. Washington: Amer Soc Microbiology, v. 55, n. 5, p. 2390-2394, 2011.
- EPM - Artigos